Organizations Filed Purposes:
THE OSTEOSARCOMA INSTITUTE WILL DEVELOP AND EXECUTE A COMPREHENSIVE, RATIONAL STRATEGY TO IMPROVE DRAMATICALLY THE LIFE EXPECTANCY OF RELAPSED AND METASTATIC OSTEOSARCOMA PATIENTS.
THE OSTEOSARCOMA INSTITUTE ESTABLISHED AN OSTEOSARCOMA INFORMATION HOTLINE AS A FREE SERVICE TO PATIENTS, IN COLLABORATION WITH THE HONORHEALTH RESEARCH INSTITUTE OF SCOTTSDALE, AZ. CALLERS SPEAK WITH AN EXPERIENCED NURSE NAVIGATOR, WHO WORKS WITH A SARCOMA EXPERT PHYSICIAN TO PROVIDE INFORMATION AND ANSWER PATIENT QUESTIONS.
THE OSTEOSARCOMA INSTITUTE COMMITTED TO FUND $200,000 FOR PHASE II MULTI-ARM CLINICAL TRIAL STUDY OF DURVALUMAB (ANTI-PD-L1) AND OLECLUMAB (ANTI-CD-73) IN ADOLESCENTS AND YOUNG ADULTS WITH RECURRENT OSTEOSARCOMA AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER. $20,000 OF THIS WAS FUNDED IN 2019.
THE OSTEOSARCOMA INSTITUTE EXECUTED AN AGREEMENT TO FUND A $500,000 PRECLINICAL AND TRANSLATIONAL SCIENCE GRANT AGREEMENT WITH CASE WESTERN RESERVE UNIVERSITY.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Dr Lee Helman | DIRECTOR/SECRETARY | 16 | $0 |
| Mary Katherine Vigness Clarke | DIRECTOR | 2 | $0 |
| Mchenry T Tichenor Jr | DIRECTOR/PRESIDENT/TREASUR | 30 | $0 |
| Bret Alexander | DIRECTOR/CHAIR | 2 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202023189349312487_public.xml